These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 27578767)

  • 61. The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs' effects on psychological flexibility.
    Wolff M; Mertens LJ; Walter M; Enge S; Evens R
    J Psychopharmacol; 2022 Mar; 36(3):387-408. PubMed ID: 35253518
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Survey of entity encounter experiences occasioned by inhaled
    Davis AK; Clifton JM; Weaver EG; Hurwitz ES; Johnson MW; Griffiths RR
    J Psychopharmacol; 2020 Sep; 34(9):1008-1020. PubMed ID: 32345112
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Psilocybin - public available psychodysleptic].
    Dydak K; Śliwińska-Mossoń M; Milnerowicz H
    Postepy Hig Med Dosw (Online); 2015 Sep; 69():986-95. PubMed ID: 26400885
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
    Grob CS; Danforth AL; Chopra GS; Hagerty M; McKay CR; Halberstadt AL; Greer GR
    Arch Gen Psychiatry; 2011 Jan; 68(1):71-8. PubMed ID: 20819978
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Psychoactive mushrooms - an update].
    Supprian T; Frey U; Supprian R; Rösler M; Wanke K
    Fortschr Neurol Psychiatr; 2001 Dec; 69(12):597-602. PubMed ID: 11753749
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Return of the psychedelics: Psilocybin for treatment resistant depression.
    Patra S
    Asian J Psychiatr; 2016 Dec; 24():51-52. PubMed ID: 27931907
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Replication and extension of a model predicting response to psilocybin.
    Russ SL; Carhart-Harris RL; Maruyama G; Elliott MS
    Psychopharmacology (Berl); 2019 Nov; 236(11):3221-3230. PubMed ID: 31203401
    [TBL] [Abstract][Full Text] [Related]  

  • 68. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride.
    Vollenweider FX; Vontobel P; Hell D; Leenders KL
    Neuropsychopharmacology; 1999 May; 20(5):424-33. PubMed ID: 10192823
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Psilocybin: a pharmacological profile.
    Aboul-Enein HY
    Am J Pharm Sci Support Public Health; 1974; 146(3):91-5. PubMed ID: 4853936
    [No Abstract]   [Full Text] [Related]  

  • 70. [Hallucinogenic mushrooms and psilocybine].
    DEYSSON G
    Proc Pharm Soc Egypt; 1960 Jan; 15():27-9. PubMed ID: 24546366
    [No Abstract]   [Full Text] [Related]  

  • 71. Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin.
    Maclean KA; Leoutsakos JM; Johnson MW; Griffiths RR
    J Sci Study Relig; 2012 Dec; 51(4):721-737. PubMed ID: 23316089
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.
    Kraehenmann R; Preller KH; Scheidegger M; Pokorny T; Bosch OG; Seifritz E; Vollenweider FX
    Biol Psychiatry; 2015 Oct; 78(8):572-81. PubMed ID: 24882567
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions.
    Barrett FS; Robbins H; Smooke D; Brown JL; Griffiths RR
    Front Psychol; 2017; 8():1238. PubMed ID: 28790944
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
    Griffiths RR; Johnson MW; Carducci MA; Umbricht A; Richards WA; Richards BD; Cosimano MP; Klinedinst MA
    J Psychopharmacol; 2016 Dec; 30(12):1181-1197. PubMed ID: 27909165
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Psychedelics and health behaviour change.
    Teixeira PJ; Johnson MW; Timmermann C; Watts R; Erritzoe D; Douglass H; Kettner H; Carhart-Harris RL
    J Psychopharmacol; 2022 Jan; 36(1):12-19. PubMed ID: 34053342
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Psilocybin-assisted therapy for depression: How do we advance the field?
    Meikle SE; Liknaitzky P; Rossell SL; Ross M; Strauss N; Thomas N; Murray G; Williams M; Castle DJ
    Aust N Z J Psychiatry; 2020 Mar; 54(3):225-231. PubMed ID: 31752499
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The hidden therapist: evidence for a central role of music in psychedelic therapy.
    Kaelen M; Giribaldi B; Raine J; Evans L; Timmerman C; Rodriguez N; Roseman L; Feilding A; Nutt D; Carhart-Harris R
    Psychopharmacology (Berl); 2018 Feb; 235(2):505-519. PubMed ID: 29396616
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population.
    Hendricks PS; Thorne CB; Clark CB; Coombs DW; Johnson MW
    J Psychopharmacol; 2015 Mar; 29(3):280-8. PubMed ID: 25586402
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Between prohibitions: patterns and meanings of magic mushroom use in the UK.
    Riley SC; Blackman G
    Subst Use Misuse; 2008; 43(1):55-71. PubMed ID: 18189205
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Levels of psilocybin and psilocin in various types of mushrooms].
    Stríbrný J; Borovicka J; Sokol M
    Soud Lek; 2003 Jul; 48(3):45-9. PubMed ID: 14631713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.